Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
33%
Ph phase_2
1
33%
Ph early_phase_1
1
33%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Active, not recruiting1
Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (33.3%)
Phase 11 (33.3%)
Phase 21 (33.3%)

Trials by Status

active_not_recruiting133%
completed133%
not_yet_recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
not_yet_recruitingphase_2

A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major

NCT07489196
completedphase_1

A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major

NCT06291961
active_not_recruitingearly_phase_1

Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major

NCT06065189

Clinical Trials (3)

Showing 3 of 3 trials
NCT07489196Phase 2

A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major

Not Yet Recruiting
NCT06291961Phase 1

A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major

Completed
NCT06065189Early Phase 1

Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major

Active Not Recruiting

All 3 trials loaded

Drug Details

Intervention Type
GENETIC
Total Trials
3